Clinical Scorecard: Comprehensive Transcriptomic Analysis of Single Cells and Bulk Samples Uncovers UBE2F as a Key Regulator of Ubiquitination Dysregulation in cDC1 During Sepsis

At a Glance

Key Highlights

• cDC1 identified as the most transcriptionally perturbed immune cell subset with pronounced ubiquitination activation in sepsis
• Four ubiquitination-related genes (CUL1, UBE2F, UBE2N, UBE3A) demonstrate reproducible diagnostic performance across independent cohorts
• Silencing UBE2F suppresses dendritic cell activation, reduces proinflammatory cytokines and organ injury, improving survival in septic mouse models

Guideline-Based Recommendations

Diagnosis

• Consider assessment of ubiquitination-related gene expression, particularly UBE2F, as potential diagnostic biomarkers in sepsis
• Utilize transcriptomic profiling approaches to identify immune cell subset perturbations in sepsis

Management

• Target UBE2F to modulate dendritic cell activation and inflammatory responses as a potential therapeutic strategy
• Incorporate interventions addressing ubiquitination dysregulation to reduce organ injury in sepsis

Monitoring & Follow-up

• Monitor expression levels of key ubiquitination genes (CUL1, UBE2F, UBE2N, UBE3A) to evaluate disease progression and treatment response

Risks

• Dysregulated ubiquitination in cDC1 contributes to excessive inflammation and organ dysfunction in sepsis
• Inadequate modulation of ubiquitination pathways may worsen immune dysregulation and clinical outcomes

Patient & Prescribing Data

Sepsis patients exhibiting immune dysregulation and organ dysfunction

Experimental silencing of UBE2F in preclinical models reduces dendritic cell activation and inflammation, suggesting therapeutic potential to improve survival

Clinical Best Practices

• Integrate single-cell and bulk transcriptomic analyses to identify key immune cell subsets and molecular targets in sepsis
• Focus on cDC1 and ubiquitination pathways for precision diagnostics and targeted therapies
• Validate biomarker candidates such as UBE2F across multiple cohorts before clinical application
• Employ multi-algorithm feature selection and network biology approaches for robust biomarker discovery

References

• NCBI GEO datasets GSE167363 and GSE220189
• Sequential Organ Failure Assessment (SOFA) score